258 related articles for article (PubMed ID: 8895687)
1. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
[TBL] [Abstract][Full Text] [Related]
2. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
3. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
4. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
[TBL] [Abstract][Full Text] [Related]
7. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
Chomel JC; Brizard F; Veinstein A; Rivet J; Sadoun A; Kitzis A; Guilhot F; Brizard A
Blood; 2000 Jan; 95(2):404-8. PubMed ID: 10627442
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.
Lo Coco F; Mandelli F; Diverio D; Alimena G; De Fabritiis P; Meloni G; Cedrone M; Frontani M; Guerrasio A; Saglio G
Bone Marrow Transplant; 1990 Oct; 6(4):253-8. PubMed ID: 2085700
[TBL] [Abstract][Full Text] [Related]
9. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha 2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion.
Pardini S; Addis M; Dore F; Bonfigli S; Nieddu RM; Galanello R; Longinotti M; Pau MG
Haematologica; 1994; 79(6):540-1. PubMed ID: 7896213
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
[TBL] [Abstract][Full Text] [Related]
12. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
Stock W; Westbrook CA; Peterson B; Arthur DC; Szatrowski TP; Silver RT; Sher DA; Wu D; Le Beau MM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 Jan; 15(1):26-36. PubMed ID: 8996121
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia.
Blennerhassett GT; Furth ME; Anderson A; Burns JP; Chaganti RS; Blick M; Talpaz M; Dev VG; Chan LC; Wiedemann LM
Leukemia; 1988 Oct; 2(10):648-57. PubMed ID: 3050293
[TBL] [Abstract][Full Text] [Related]
14. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
15. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Emig M; Saussele S; Wittor H; Weisser A; Reiter A; Willer A; Berger U; Hehlmann R; Cross NC; Hochhaus A
Leukemia; 1999 Nov; 13(11):1825-32. PubMed ID: 10557058
[TBL] [Abstract][Full Text] [Related]
16. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
[TBL] [Abstract][Full Text] [Related]
17. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
18. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
Talwar R; Choudhry VP; Jobanputra V; Kucheria K
Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic analysis and bcr/abl mRNA detection in chronic myeloid leukemia].
Yao B; Guo M; Pian H
Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):137-9. PubMed ID: 11601240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
